Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Name: Αlpha¹ Rigor Record — Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Item: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Rating: 96
Author: Αlpha¹

Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial with clear randomization, stratification, power analysis, and ethical approvals. The main methodological weakness is the lack of a formal data availability statement and unspecified statistical software, which are minor reporting gaps. The statistical analyses are appropriate and the reported tests recomputed consistently.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence to reconcile. The study is an interventional trial; animal-related and bench-resource sub-criteria were marked not applicable. The statistics verification covered only 5 tests with test statistics/CI; other p-values (e.g., threshold-only) were not machine-verified and remain unverified, not confirmed.

7 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies on blinatumomab in relapsed pediatric B-ALL and adult E1910, and identifies the knowledge gap for newly diagnosed pediatric patients. The rationale is logical: blinatumomab improves outcomes in relapsed disease, so it may benefit newly diagnosed patients. Limitations of prior work are implicitly addressed by noting the need for pediatric-specific data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 1]

“Blinatumomab improves outcomes among children with relapsed B-ALL. – Among adults, the E1910 study found that adding blinatumomab to standard chemotherapy increased relapse-free and overall survival among adults with newly diagnosed disease.”